Ketamine Therapy for Depression in Asheville
For patients with depression that has not responded adequately to multiple antidepressants, ketamine therapy offers a different mechanism of action. Physician-led care, ER-trained nursing team, medical evaluation before treatment.
When Antidepressants Aren’t Enough
About one in three people with major depressive disorder do not experience adequate symptom relief after trying two or more standard antidepressant medications at full dose. The clinical term is treatment-resistant depression. The lived experience is more brutal: months or years of trying medications, side effects, and waiting for something to work.
Ketamine acts on different receptor systems than SSRIs and SNRIs. For some patients, that different mechanism produces a response within hours or days, rather than the four to six weeks typical for standard antidepressants. The response is not universal, and it is not permanent without ongoing care, but the evidence base is substantial.
This page explains how ketamine therapy works for depression, what the treatment process looks like, and how to determine whether it might be the right option for you.
What the Research Shows
Ketamine’s antidepressant effects were first documented in the early 2000s. Since then, dozens of peer-reviewed studies have examined IV ketamine for major depressive disorder and treatment-resistant depression. Key findings:
- Rapid onset. Many patients experience symptom reduction within 24 hours of a first infusion. This contrasts with the 4 to 6 week onset typical of SSRIs.
- Substantial response rates. Meta-analyses of randomized controlled trials report response rates of 50 to 70 percent for patients with treatment-resistant depression, with remission rates in the 30 to 40 percent range.
- Durability requires maintenance. A single infusion produces effects lasting roughly one to two weeks for most responders. Series protocols (4 to 6 infusions over 2 to 3 weeks) followed by maintenance dosing produce more durable responses.
- FDA-approved esketamine. In 2019 the FDA approved Spravato (esketamine), a nasal spray form of ketamine, for treatment-resistant depression at REMS-certified providers.
How Ketamine Differs from Antidepressants
Most antidepressants target serotonin, norepinephrine, or dopamine systems. Ketamine works primarily on the glutamate system through NMDA receptor antagonism, with downstream effects on synaptic plasticity (the brain’s ability to form new neural connections).
This is a different chemical conversation. For patients who have not responded to multiple medications targeting monoamine systems, opening a different pathway is meaningful.
This does not mean ketamine replaces other treatments. Many patients continue antidepressants, therapy, and lifestyle work alongside ketamine therapy. The integration of approaches is part of what your clinician will discuss during your evaluation.
Who May Be a Good Candidate
Ketamine therapy may be considered for adults with:
- Major depressive disorder
- Treatment-resistant depression (typically defined as failure of two or more antidepressant trials at adequate dose and duration)
- Severe depressive symptoms with significant functional impairment
- Depression with acute suicidal ideation (in a clinically appropriate setting)
- Bipolar depression (with careful clinical judgment and coordination with a psychiatrist)
You may not be a candidate if you have:
- Uncontrolled hypertension or cardiovascular disease
- A history of psychotic disorders without psychiatric collaboration
- Active substance use disorder (case-by-case clinical review)
- Pregnancy
- Other conditions identified during medical evaluation
The medical evaluation is the only way to determine fit. We do not screen on the phone consult.
What Treatment Looks Like at Hydrate Asheville
Phone Consult
Free, about 15 minutes. You ask questions. We answer them. If ketamine therapy is a likely fit, we schedule your medical evaluation.
Medical Evaluation
A licensed clinician reviews your medical history, current medications, mental health history, prior treatments, and treatment goals. They explain the protocol, the expected experience during infusion, possible side effects, and the maintenance plan.
Initial Treatment Series
Most patients begin with 4 to 6 infusions over 2 to 3 weeks. 40 to 60 minutes of active infusion in a private treatment room, vitals monitored by an ER-trained nurse, 30 minutes of recovery before discharge to your driver.
Maintenance Dosing
After the initial series, your clinician will recommend a maintenance schedule based on your response. Common schedules are one infusion every 2 to 6 weeks, adjusted based on symptom tracking and clinical judgment.
Integration and Therapy Coordination
Ketamine therapy works best alongside ongoing mental health care. We coordinate with your existing therapist or psychiatrist when you give written consent.
Ketamine Infusion vs. KAP for Depression
Both approaches use ketamine. The difference is who is in the room and what happens during the session.
Ketamine Infusion Therapy
Medically supervised. Nursing staff monitor vital signs and provide a calm, supportive environment. There is no active psychotherapy during the session. This is the more common approach for major depressive disorder and treatment-resistant depression when the clinical goal is symptom reduction.
Ketamine-Assisted Psychotherapy (KAP)
Adds a licensed therapist who is present during and after the dosing session. KAP is often a stronger fit for depression with significant trauma components, complex grief, or when the patient wants active integration of insights during the experience.
Costs
Ketamine therapy for depression is typically not covered by insurance and is paid out of pocket. HSA and FSA accepted where eligible. Payment plans available for series treatment.
We provide a clear written estimate before treatment begins. No surprise charges.
Frequently Asked Questions
How fast does ketamine work for depression?
Many patients notice symptom reduction within 24 hours of the first infusion. Full response usually develops over the initial series of 4 to 6 sessions. Response is not universal.
Will I stop my current antidepressant?
That decision is between you and your prescribing physician. Most patients continue antidepressants during ketamine therapy. Some taper after a positive response under their physician’s supervision.
Is ketamine addictive?
Ketamine has a recognized abuse potential in unsupervised settings. Used in a clinically supervised infusion protocol at therapeutic doses, the risk of dependence is considered low. We screen for substance use history during evaluation.
What does the infusion feel like?
Most patients experience dissociation during infusion (a sense of being separated from one’s body or surroundings, changes in perception of time, altered visual experience). The effects begin within minutes and resolve within an hour after the session ends. Most patients describe the experience as interesting or peaceful; some find it uncomfortable. Your clinician prepares you for what to expect.
How is this different from Spravato?
Spravato is intranasal esketamine, FDA approved for treatment-resistant depression and only available at REMS-certified providers. IV ketamine allows for individualized dosing protocols and use across a broader range of conditions. See full comparison →
Can ketamine help if I have bipolar disorder?
Possibly, but bipolar depression requires careful coordination with a psychiatrist due to risk of triggering manic or hypomanic episodes. We require collaboration with a managing psychiatrist for patients with bipolar disorder.
What if I don’t respond?
Not every patient responds to ketamine therapy. If your initial series does not produce meaningful response, your clinician will discuss next steps, which may include adjusting the protocol, trying KAP, or referring you for other treatment options.
Ready to Talk?
Book a free 15-minute phone consult. We’ll answer your questions and let you decide.
Visit: Hydrate Medical Asheville, 190 Hendersonville Rd Suite 30, Asheville, NC 28803
Ketamine therapy is not appropriate for every patient. A medical evaluation by a licensed clinician is required prior to treatment. Individual results vary. This page is educational and is not a substitute for medical advice. Hydrate Medical does not promise outcomes.
Sources
- Krystal JH, et al. Ketamine: A Paradigm Shift for Depression Research and Treatment. Neuron, 2019.
- Murrough JW, et al. Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression. American Journal of Psychiatry, 2013.
- FDA Approval Documentation, Spravato (esketamine), 2019.
- American Psychiatric Association Task Force on Treatment Resistance.